Search Results - "Hunault-Berger, Mathilde"

Increased apoptosis in mononucleated cells but not in CD34⁺ cells in blastic forms of myelodysplastic syndromes.

Authors: Berger, Gaëtan Hunault-Berger, Mathilde Rachieru, Petronela et al.

Source: Hematology Journal. 2001, Vol. 2 Issue 2, p87. 10p.

Lymphomatoid Granulomatosis and Tuberculosis, Coincidence or Cohabitation—A Case Report.

Authors: Giachetti, Nicolas Bellal, Sarah Schwarz, Marianne et al.

Source: Lymphatics. Sep2025, Vol. 3 Issue 3, p28. 6p.

A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial

Authors: Chevallier, Patrice Hunault-Berger, Mathilde Larosa, Fabrice et al.

Source: Leukemia Research. Aug2009, Vol. 33 Issue 8, p1124-1126. 3p.

Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma.

Authors: Vély, Agathe Couturier, Marie-Anne Delepine, Pascal et al.

Source: Leukemia & Lymphoma. Dec2023, Vol. 64 Issue 13, p2178-2187. 10p.

Clusterin and pentraxin 3 are markers of severity during febrile neutropenia in adults with haematological malignancies receiving intensive chemotherapy.

Authors: Mallebranche, Coralie Mosnier, Carole Orvain, Corentin et al.

Source: British Journal of Haematology. Sep2025, Vol. 207 Issue 3, p780-788. 9p.

Implementation of a new blood cultures sampling strategy in patients receiving intensive chemotherapy for acute leukemia and/or hematopoietic cell transplantation.

Authors: Declerck, Charles Giltat, Aurélien Boutemy, Romane et al.

Source: Leukemia & Lymphoma. Jun2023, Vol. 64 Issue 6, p1204-1207. 4p.

Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial.

Authors: Drevin, Guillaume Briet, Marie Bazzoli, Caroline et al.

Source: Pharmaceutics. Apr2022, Vol. 14 Issue 4, pN.PAG-N.PAG. 12p.

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.

Authors: de Botton, Stéphane Brandwein, Joseph M. Wei, Andrew H. et al.

Source: Cancer Medicine. Sep2021, Vol. 10 Issue 18, p6336-6343. 8p.

Intestinal derivation for digestive complications of graft versus host disease in adult patients: A case series and review of the literature.

Authors: Desprez, Christophe François, Sylvie Thepot, Sylvain et al.

Source: Trends in Transplantation. Sep2021, Vol. 14 Issue 3, p1-5. 5p.

Unusual peripheral T-cell lymphoma with a cytotoxic phenotype presenting in the pancreas.

Authors: Dubois, Juliette Bellal, Sarah Copin, Marie-Christine et al.

Source: Annals of Hematology. Mar2025, Vol. 104 Issue 3, p2045-2049. 5p.

Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate‐risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006‐intermediate‐risk trial

Authors: Bouvier, Anne Hamel, Jean‐François Delaunay, Jacques et al.

Source: European Journal of Haematology. Jul2021, Vol. 107 Issue 1, p111-121. 11p.

Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.

Authors: Couturier, Marie-Anne Thomas, Xavier Raffoux, Emmanuel et al.

Source: Leukemia & Lymphoma. Mar2021, Vol. 62 Issue 3, p620-629. 10p.

R‐DHA‐oxaliplatin (R‐DHAOx) versus R‐DHA‐cisplatin (R‐DHAP) regimen in B‐cell lymphoma treatment: A eight‐year trajectory study.

Authors: Lacout, Carole Orvain, Corentin Seegers, Valérie et al.

Source: European Journal of Haematology. Aug2020, Vol. 105 Issue 2, p223-230. 8p.

Conditioning‐based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991‐2012) on behalf of EBMT CMWP.

Authors: Hayden, Patrick J. Iacobelli, Simona Pérez‐Simón, José Antonio et al.

Source: European Journal of Haematology. Mar2020, Vol. 104 Issue 3, p181-189. 9p.

Donor cell‐derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation.

Authors: Bouvier, Anne Ribourtout, Bénédicte François, Sylvie et al.

Source: European Journal of Haematology. Oct2018, Vol. 101 Issue 4, p570-574. 5p.

Toxicity Profile According to Etoposide and Cytarabine Dosing in Patients with Lymphoma Receiving Autologous Stem Cell Transplantation Following BEAM Conditioning.

Authors: Vely, Agathe Paillassa, Jérôme Nunes Gomes, Christopher et al.

Source: Annals of Hematology. Aug2023, Vol. 102 Issue 8, p2225-2231. 7p.

Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.

Authors: Cahu, Xavier Carré, Martin Recher, Christian et al.

Source: European Journal of Haematology. May2017, Vol. 98 Issue 5, p443-449. 7p.

Different number of circulating CD34 + cells in essential thrombocythemia, prefibrotic/early primary myelofibrosis, and overt primary myelofibrosis.

Authors: Luque Paz, Damien Cottin, Laurane Lippert, Eric et al.

Source: Annals of Hematology. Apr2022, Vol. 101 Issue 4, p893-896. 4p.

Slower degradation rate of cytarabine in blood samples from acute myeloid leukemia by comparison with control samples.

Authors: Abbara, Chadi Drevin, Guillaume Férec, Séverine et al.

Source: Cancer Chemotherapy & Pharmacology. Nov2020, Vol. 86 Issue 5, p687-691. 5p.

Sequential mutational evaluation of CALR ‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.

Authors: Cottin, Laurane Riou, Jérémie Orvain, Corentin et al.

Source: British Journal of Haematology. Mar2020, Vol. 188 Issue 6, p935-944. 10p. 2 Charts, 4 Graphs.